S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.

Detalles Bibliográficos
Autor principal: Marchetti, Monia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Oral Sessions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428278/
http://dx.doi.org/10.1097/01.HS9.0000968160.75533.11
_version_ 1785090429677469696
author Marchetti, Monia
author_facet Marchetti, Monia
author_sort Marchetti, Monia
collection PubMed
description
format Online
Article
Text
id pubmed-10428278
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104282782023-08-17 S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM. Marchetti, Monia Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428278/ http://dx.doi.org/10.1097/01.HS9.0000968160.75533.11 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Oral Sessions
Marchetti, Monia
S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
title S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
title_full S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
title_fullStr S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
title_full_unstemmed S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
title_short S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
title_sort s312: is brexucabtagene autoleucel a cost-effective treatment for refractory/relapsed acute lymphoblastic leukemia? a pharmacoeconomic analysis in the perspective of the public healthcare system.
topic Oral Sessions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428278/
http://dx.doi.org/10.1097/01.HS9.0000968160.75533.11
work_keys_str_mv AT marchettimonia s312isbrexucabtageneautoleucelacosteffectivetreatmentforrefractoryrelapsedacutelymphoblasticleukemiaapharmacoeconomicanalysisintheperspectiveofthepublichealthcaresystem

Ejemplares similares